Business Wire

Mary Kay Inc. Earns Several Awards for Work in Business, COVID-19 Response and Sustainability Efforts

11.8.2021 16:03:00 EEST | Business Wire | Press release

Share

In 2021, Mary Kay Inc. continued its decades-long commitment to enriching the lives of women around the globe, manufacturing irresistible products and building healthier, more sustainable communities even in response to COVID-19. In recognition of Mary Kay’s achievements in the last six months, the brand has taken home several coveted awards in the business, corporate citizenship, and leadership categories from various prestigious organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005163/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mary Kay was named a Silver Globee® Winner in 3 categories at the 13th Annual 2021 Golden Bridge Business and Innovation Awards. (Graphic: Mary Kay Inc.)

The awards, which range from recognition of the brand’s COVID-19 response to accolades for a Mary Kay-produced documentary on the Gulf of Mexico’s preservation efforts, highlight the company’s unwavering business values and its dedication to the principles defined by the brand’s legendary founder, Mary Kay Ash.

Latest awards include:

COVID-19 Response Awards

  • Silver Globee® Winner – 13th Annual 2021 Golden Bridge Business and Innovation Awards
    • Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
    • Company Response of the Year (Mary Kay Inc.)
    • Best Product To Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
  • Gold Globee® Winner – 13th Annual 2021 Golden Bridge Business and Innovation Awards
    • Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM)
  • Silver Globee® Winner – 6th Annual 2021 American Best in Business Awards
    • Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
    • Company Response of the Year (Mary Kay Inc.)
    • Best Product to Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
  • Gold Globee® Winner – 6th Annual 2021 American Best in Business Awards
    • Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM)

Company Awards

  • America's Best Mid-Sized Employers 2021 – Forbes
  • “Power of Woman” Award, Mary Kay Ukraine, joint project with Marie Claire - X-RAY Marketing Awards
  • The Best Employer 2021, Mary Kay Poland – The Financial Magazine
  • Direct Sales Cosmetic Company Number One Award,Mary Kay Belarus – “Number One” Annual National Awards

Sustainability Awards

Guardians of the Gulf, an eye-opening documentary that explores the tumultuous relationship between the Gulf of Mexico and the conservationists determined to protect it, has received various awards. Mary Kay Inc., serving as executive producer, with Media One in partnership with The Nature Conservancy, visited the coasts of Texas, Alabama and Mexico to shed light on the often-untold stories of Gulf preservation.

  • Silver: Non-Broadcast General-Nature/Wildlife – Telly Awards
  • Bronze: Non-Broadcast General-Documentary – Telly Awards
  • Best Special Focus Documentary Finalist – LA Femme International Film Festival
  • World Remi Award – Worldfest Houston International Film Festival

Leadership Recognition

  • “67 Powerful Black Women CEOs And Executives In Corporate America,” Julia Simon, Chief Legal Officer and Corporate Secretary / Sheryl Adkins-Green, Chief Marketing Officer – Business Insider
  • “TOP Women CEOs in Ukraine” in Women’s Leadership in the Corporate Sector and Business rating - Viktoriia Zoria-Iatsenko, General Manager, Mary Kay Ukraine – WoMo (The Portal for Working Women)
  • “50 Most Valuable Women in Poland,” Ewa Kudlińska-Pyrz, General Manager, Mary Kay Poland – The Financial Magazine
  • “The Top 100 Women Leaders In Consumer Products Of 2021,” Allyson Sellers, Vice President of Sales, Mary Kay U.S. – Women We Admire

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye